Sergqpm at 09:03, 18 February 2026

2026-02-18T09:03:52Z

New page

{{Short description|Indian multinational pharmaceutical company}}
{{More citations needed|date=February 2017}}
{{Use dmy dates|date=January 2019}}
{{Use Indian English|date=January 2019}}
{{Infobox company
| name = Aurobindo Pharma Limited
| logo = File:Aurobindo Pharma logo.svg
| logo_size = 250px
| logo_alt = Aurobindo Pharma's Logo
| logo_caption =
| logo_padding =
| image =
| image_size =
| image_alt =
| image_caption =
| native_name =
| native_name_lang = 
| romanized_name =
| former_name =
| type = [[Public company|Public]]
| traded_as = {{NSE|AUROPHARMA }} {{BSE|524804}}
| ISIN =
| industry = [[Pharmaceutical industry|Pharmaceuticals]]
| products = {{hlist|[[Pharmaceutical]]s |[[generic drug]]s |[[over-the-counter drug]]s |[[vaccine]]s |[[Medical diagnosis|diagnostics]] |[[contact lens]]es |[[Veterinary medicine|animal health]]<ref>{{ cite web |url=https://www.aurobindo.com/wp-content/uploads/2020/08/Aurobindo-Pharma-Limited-Annual-Report-2019-20.pdf |title=Aurobindo Pharma Limited Annual Report 2019-20 |archive-url=https://web.archive.org/web/20200813125147/https://www.aurobindo.com/wp-content/uploads/2020/08/Aurobindo-Pharma-Limited-Annual-Report-2019-20.pdf |archive-date=2020-08-13 |url-status=dead}}</ref> }}
| fate =
| predecessor = 
| successor = 
| founded = {{Start date and age|1986}} 
| founders = V. Ramprasad Reddy<ref name="Auro_01"/> K. Nityananda Reddy<ref name="Auro_01">{{cite web| url=https://www.aurobindo.com/about-us/ | title=Aurobindo Overview}}</ref>
| defunct = 
| hq_location = [[Hyderabad]], [[Telangana]], India
| hq_location_city =
| hq_location_country =
| num_locations =
| num_locations_year = 
| area_served =
| brands =
| production =
| production_year = 
| services =
| revenue = {{increase}} {{INRConvert|31724|c}} (2025)
| operating_income = {{increase}} {{INRConvert|6605|c}} (2025)
| net_income = {{increase}} {{INRConvert|3484|c}} (2025)
| assets = {{increase}} {{INRConvert|49748|c}} (2025)
| equity = {{increase}} {{INRConvert|32646|c}} (2025)
| owner = 
| members =
| members_year = 
| num_employees = 23,000<ref>{{cite web |url=http://www.aurobindo.com/docs/annual-reports/aurobindo-ar-2016-17.pdf |title=Aurobindo Pharma Limited Annual Report 2016-17 |archive-url=https://web.archive.org/web/20220121001625/https://aurobindo.com/docs/annual-reports/aurobindo-ar-2016-17.pdf |archive-date=21 January 2022 |url-status=dead}}</ref>
| num_employees_year = 2020
| parent =
| divisions =
| subsid =
| module = 
| ratio = 
| rating = 
| website = {{URL|http://www.aurobindo.com/}}
| footnotes = Financials {{as of|2025|03|31|lc=y|df=yes}}.<ref>{{cite web |title=Audited consolidated financial results for year ended March 31, 2025 |url=https://www.aurobindo.com/api/uploads/resultsannouncement/LtrToSEsOutcomeofBM26052025.pdf |publisher=Aurobindo Pharma |access-date=27 May 2025}}</ref>
}}

'''Aurobindo Pharma Limited''' is an Indian multinational [[pharmaceutical]] manufacturing company based in [[HITEC City]], [[Hyderabad]], with U.S. [[headquarters]] in [[East Windsor, New Jersey|East Windsor]], [[Mercer County, New Jersey|Mercer County]], [[New Jersey]]. The company manufactures [[Generic drug|generic]] pharmaceuticals and [[Active ingredient|active pharmaceutical ingredients]]. The company's area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics.<ref name=":0">{{Cite web|url=https://www.brandindiapharma.in/pharmaceutical-companies-india/aurobindo-pharma-ltd|title=Aurobindo Pharma Ltd: Company Overview, History, Contacts {{!}} Brand India Pharma|website=www.brandindiapharma.in|access-date=2019-10-15}}</ref> The company markets these products in over 125 countries.<ref name=":0" /> Its marketing partners include [[Pfizer]]<ref>[https://web.archive.org/web/20140331072735/http://articles.economictimes.indiatimes.com/2010-11-05/news/27598030_1_net-profit-aurobindo-pharma-forex-gains "Pfizer, Astra deals to drive Aurobindo Pharma's growth"], ''The Economic Times'', 5 November 2010</ref> and [[AstraZeneca]].
<ref>[https://web.archive.org/web/20140331053923/http://articles.economictimes.indiatimes.com/2010-09-06/news/27603805_1_aurobindo-pharma-dosage-and-sterile-products-uk-mhra "Aurobindo Pharma signs supply pact with AstraZeneca"], ''The Economic Times'', 6 September 2010</ref>

==History==
[[File:Clindamycin.jpg|thumb|Aurobindo Pharma [[clindamycin]] capsules]]
The company commenced operations in 1988–89 with a single unit manufacturing semi-synthetic [[penicillin]] (SSP) in [[Puducherry (union territory)|Puducherry]]. Aurobindo Pharma became a [[public company]] in 1992 and listed its shares on the Indian [[stock exchange]]s in 1995. Aurobindo Pharma also has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterologicals, and cephalosporins, among others.

Aurobindo Pharma features among the top 10 companies in India in terms of consolidated revenues.<ref name=":0" /> Aurobindo exports to over 125 countries with more than 70% of its revenues derived out of international operations, primarily from the U.S.

In 2014, Aurobindo purchased the generic operations of [[Actavis]] in seven Western European countries for US$41 million.<ref>{{cite news | type=paper | date=15 February 2014 | volume=34 | issue=4 | page=10 | work=[[Gen. Eng. Biotechnol. News]] | title=Aurobindo Buys Actavis' European Operations | department=News: Industry Watch }}</ref><ref>{{cite news|url=http://www.btvin.com/videos/watch/5197/aurobindo-to-buyout-actavis%27-eu-ops|archive-url=https://web.archive.org/web/20141024025904/http://www.btvin.com/videos/watch/5197/aurobindo-to-buyout-actavis%27-eu-ops|url-status=usurped|archive-date=24 October 2014|title=Aurobindo To Buyout Actavis' EU Ops|accessdate=20 January 2014| publisher=Bloomberg TV India}}</ref>

===Business expansion===
Aurobindo Pharma plans to expand its product portfolio with high-value products in [[oncology]], [[hormones]], [[biosimilars]], and novel drug delivery solutions like depot injections, inhalers, patches, and films. It has also set its sights on geographic expansion in new territories like [[Poland]], [[Italy]], [[Spain]], [[Czech Republic]], [[Portugal]], and [[France]], as the generic drug market in these countries is relatively small.<ref>{{cite news | url=https://www.thehindubusinessline.com/companies/aurobindo-pharma-to-focus-on-highvalue-products-in-us/article9722248.ece | title=Aurobindo Pharma to focus on high-value products in US | date=12 January 2018 | newspaper=Business Line | first=G Naga | last=Sridhar | accessdate=6 January 2019}}</ref>

In 2017, Aurobindo Pharma inked a pact to acquire Portugal's [[Generis Farmaceutica|Generis Farmaceutica SA]] from Magnum Capital Partners for a consideration of €135 million.<ref>{{Cite web|last=PTI|date=2017-01-07|title=Aurobindo Pharma to acquire Portugal's Generis for €135 million|url=https://www.livemint.com/Companies/lv3KqcJ8s1e5hn68BKyfEO/Aurobindo-Pharma-to-acquire-Portugals-Generis-for-135-mill.html|access-date=2021-04-12|website=mint|language=en}}</ref> It also acquired four biosimilar products from Swiss firm TL Biopharmaceutical AG.<ref>{{Cite web|last=Trivedi|first=Isha|date=2017-02-10|title=Aurobindo Pharma buys 4 biosimilar products from TL Biopharmaceutical|url=https://www.livemint.com/Companies/HeABAdTWeZEUHYDmNMxzcJ/Aurobindo-Pharma-buys-4-biosimilar-products-from-TL-Biopharm.html|access-date=2021-04-12|website=mint|language=en}}</ref>

Aurobindo Pharma Ltd. signed a definitive agreement to purchase the Apotex businesses in Poland, the Czech Republic, the [[Netherlands]], Spain and [[Belgium]]. The agreement is conditional on the receipt of competition clearances for the transaction by the Dutch and Polish authorities. As part of the proposed sale, Apotex will enter into a transitional manufacturing and supply arrangement with Aurobindo to support the ongoing growth plans of these businesses.<ref>{{Cite press release|last=Limited|first=Aurobindo Pharma|title=Aurobindo Signs a Definitive Agreement to Acquire Apotex' Businesses in Poland, Czech Republic, the Netherlands, Spain and Belgium|url=https://www.prnewswire.com/news-releases/aurobindo-signs-a-definitive-agreement-to-acquire-apotex-businesses-in-poland-czech-republic-the-netherlands-spain-and-belgium-808992512.html|access-date=2021-04-12|agency=PR Newswire|language=en}}</ref>

In May 2024, TheraNym Biologics, a wholly owned subsidiary of Aurobindo Pharma Ltd signed a pact with [[Merck & Co.]] for expanding its biologics manufacturing facilities and exploring contract manufacturing operations for biologics.<ref>{{Cite web |title=Aurobindo arm TheraNym inks pact with MSD for biologics manufacturing|url=https://www.business-standard.com/companies/news/aurobindo-arm-theranym-inks-pact-with-msd-for-biologics-manufacturing-124053101785_1.html|access-date=2024-06-01|work=Business Standard}}</ref>

==Legal issues==
In December 2016, 20 American [[State attorney general|attorneys general]] filed a [[Lawsuit|civil complaint]] accusing Aurobindo Pharma of a coordinated scheme to artificially maintain high prices for a generic antibiotic and diabetes drug. The complaint alleged [[Price fixing|price collusion schemes]] between six pharmaceutical firms including informal gatherings, telephone calls, and text messages.<ref>{{cite news |last=Thomas |first=Katie |url=https://www.nytimes.com/2016/12/15/business/generic-drug-price-lawsuit-teva-mylan.html |title=20 States Accuse Generic Drug Companies of Price Fixing |work=[[The New York Times]] |date=2016-12-15 |accessdate=2016-12-16 }}</ref>

On 11 April 2018, Aurobindo was featured in the Dutch documentary television program ''[[Zembla (TV series)|Zembla]]''.<ref>{{Cite web|title='Manufacturer of Dutch medicines exploit workers and pollute the environment' - Zembla - BNNVARA|url=https://www.bnnvara.nl/zembla/artikelen/manufacturer-of-dutch-medicines-exploit-workers-and-pollute-the-environment|access-date=2021-04-12|website=Zembla|language=nl}}</ref> It details accusations against the company of both environmental damage and poor working conditions for their employees in [[Hyderabad, India]].

On 20 June 2019, Aurobindo received a warning letter from the [[US Food and Drug Administration|USFDA]] after an inspection of its drug manufacturing facility, Aurobindo Pharma Limited in [[Pydibhimavaram]], [[Srikakulam District]], [[Andhra Pradesh]].<ref>{{Cite web|last=Research|first=Center for Drug Evaluation and|date=2019-07-02|title=Aurobindo Pharma Limited - 577033 - 06/20/2019|url=https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aurobindo-pharma-limited-577033-06202019|access-date=2021-04-12|website=Center for Drug Evaluation and Research|language=en}}</ref> The warning letter summarized significant deviations from [[Good manufacturing practice|current good manufacturing practices]] (cGMP) for [[active pharmaceutical ingredients]] (API).

On 7 October 2019, Aurobindo said it received seven observations from the USFDA for its unit-7 formulation plant in Telangana, with regard to potentially misleading documentation.<ref>{{Cite news|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/documents-potentially-misleading-in-aurobindo-pharmas-unit-vii-usfda/articleshow/71522222.cms|title=Documents potentially misleading in Aurobindo Pharma's Unit-VII: USFDA|date=2019-10-10|work=The Economic Times|access-date=2019-10-15}}</ref> This caused its share prices to drop over 20%.<ref>{{Cite web|url=https://www.businesstoday.in/markets/company-stock/aurobindo-pharma-share-crashes-20-to-hit-52week-low-usfda-observations-lupin-glenmark-fall-up-to-9/story/383428.html|title=Aurobindo Pharma share crashes 20% to hit 52-week low on USFDA observations; Lupin, Glenmark fall up to 9%|website=businesstoday.in|date=7 October 2019 |access-date=2019-10-15}}</ref>

==Recalls==
{{See also|Valsartan#recalls|Angiotensin II receptor blocker#recalls}}

In 2018,<ref name=ucm629213>{{cite web |title=Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Consumer Level Recall of 80 Lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP, Due to the Detection of NDEA (N-Nitrosodiethylamine) Impurity |website=[[Food and Drug Administration]] |url=https://www.fda.gov/Safety/Recalls/ucm629213.htm |archive-url=https://web.archive.org/web/20190101134409/https://www.fda.gov/Safety/Recalls/ucm629213.htm |url-status=dead |archive-date=1 January 2019 |date=31 December 2018 |quote=Aurobindo Pharma USA, Inc. is conducting a voluntary recall of 80 lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. The impurity detected in the finished drug product is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.}}{{PD-notice}}</ref> and 2019,<ref name=ucm632442>{{cite web |title=AurobindoPharma USA, Inc. Initiates a Voluntary Nationwide Consumer Level Recall Expansion of 38 Lots of Amlodipine Valsartan Tablets USP and Valsartan Tablets, USP due to the detection of NDEA (N-Nitrosodiethylamine) Impurity |website=[[Food and Drug Administration]] |url=https://www.fda.gov/Safety/Recalls/ucm632442.htm |date=1 March 2019 |quote=AurobindoPharma USA, Inc. and Acetris Health LLC. Are conducting a voluntary recall expansion of 39 lots of Valsartan and Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug product. This recall is an expansion of the recall initiated 12/31/18 The impurity detected in the finished drug product is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.}}{{dead link|date=May 2025|bot=medic}}{{cbignore|bot=medic}}{{PD-notice}}</ref> Aurobindo Pharma USA recalled tablets containing [[valsartan]] due to the detection of [[N-Nitrosodiethylamine|''N''-Nitrosodiethylamine]] (NDEA) which is a probable human [[carcinogen]].

In November 2019, Aurobindo Pharma USA recalled [[ranitidine]] tablets, capsules, and syrup due to the detection of unacceptable levels of [[N-nitrosodimethylamine]] (NDMA).<ref>{{cite web | title=Aurobindo Pharma USA, Inc. Initiates Voluntary Nationwide Consumer Level Recall of 38 Lots of Ranitidine Tablets 150mg, Ranitidine Capsules 150mg, Ranitidine Capsules 300mg and Ranitidine Syrup 15mg/mL Due to the Detection of NDMA (Nitrosodimethylamine) Impurity | website=U.S. [[Food and Drug Administration]] (FDA) | date=6 November 2019 | url=https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/aurobindo-pharma-usa-inc-initiates-voluntary-nationwide-consumer-level-recall-38-lots-ranitidine | archive-url=https://web.archive.org/web/20191111033706/https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/aurobindo-pharma-usa-inc-initiates-voluntary-nationwide-consumer-level-recall-38-lots-ranitidine | archive-date=11 November 2019 | url-status=dead | access-date=10 November 2019 | quote=Aurobindo Pharma USA, Inc. is conducting a voluntary recall of 1 lot of Ranitidine Tablets 150mg to the retail level and 37 lots of Ranitidine Capsules 150mg, Ranitidine Capsules 300mg and Ranitidine Syrup 15mg/mL to the consumer level due to the detection of NDMA (Nitrosodimethylamine) Impurity in the finished product. The impurity detected is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.}}{{PD-notice}}</ref>

==See also==
{{portal|Companies|India|New Jersey}}
* [[Biotech and pharmaceutical companies in the New York metropolitan area]]

{{clear}}

==References==
{{Reflist}}

==External links==
* {{Official website|http://www.aurobindo.com}}

{{Nifty 200 companies}}
{{Authority control}}

[[Category:Pharmaceutical companies of India]]
[[Category:Pharmaceutical companies established in 1986]]
[[Category:Indian companies established in 1986]]
[[Category:Manufacturing companies based in Hyderabad, India]]
[[Category:Indian brands]]
[[Category:Generic drug manufacturers]]
[[Category:1986 establishments in Andhra Pradesh]]
[[Category:Companies listed on the National Stock Exchange of India]]
[[Category:Companies listed on the Bombay Stock Exchange]]
[[Category:Multinational companies headquartered in India]]

Aurobindo Pharma - Revision history

Sergqpm at 09:03, 18 February 2026